Secrecy surrounds billion-dollar aid deal for drug industry
The Nobel Prize winner Médecins Sans Frontières says a USD 1.5 billion aid deal to develop new vaccines for poor countries is much too lucrative for the drug industry. MSF has estimated an earlier version of the scheme to be overpriced by USD 600 million, but has been denied basic facts about the latest proposal.
Development Today has obtained a confidential document about the scheme sent to donors last month, which shows one company, GlaxoSmithKline, walking away with almost the whole prize. Donors are expected to settle the deal next week.